Anthony Pompliano

Now, they thought about a lot of different things.

They've ended up, one of the key components is pharmaceutical.

The idea of manufacturing drugs in zero gravity, certain things are possible that are not as either cheap or possible here on earth.

that is an external innovative shock to pharmaceutical development, right?

So there's like the science of like, what are the drugs and then how do you actually manufacture?

I think that you can go through, whether it's Bitcoin, LLM, something like Avarta, et cetera, and you can see that these external shocks, they're incredibly hard to create, but when they happen, it spreads like wildfire through an industry.

And I actually wonder how many people are Bitcoin-minded

versus people who start to recognize these patterns of, okay, I know a lot of people who are saying, look, Bitcoin, I didn't sell my Bitcoin.

I still got my Bitcoin.

Net new dollars though, they went to AI.

Net new dollars next are going to go to humanoid robots.

Net new dollars from that are going to go to, you know, pharmaceutical development.

Like they're actually innovation investors, not just Bitcoin investors.

And I think that that ability maybe is actually going to become a very core skill that's important kind of for the world that we're going into.

You agree with that?

Never thought we'd talk about pharmaceuticals on here, but I'm here for it.

I think Ken Langone, if I understand, if I remember correctly, his average holding period is 42 years in his portfolio.

Like just go, right?

And if I remember correctly, he has held Eli Lilly for something like 40 something years and still holds the position today.

When you look at the market moving forward, Bitcoin is up, let's call it 6% over the last year, 4% year to date, atrocious performance in Bitcoiners' minds, atrocious, right?